Medical Device Network on MSN
Hims & Hers Health signs agreement to acquire YourBio Health
The transaction closure is anticipated in early 2026, contingent on regulatory approvals and other customary conditions.
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...
Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...
What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...
Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% ...
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, ...
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Hims & Hers Health, Inc. (HIMS) reports results for the quarter ended September 2025. While this widely-known ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback